House votes to push FDA toward ending routine animal testing of new drugs

Congress already let drugmakers skip animal tests in 2022. The FDA never updated the paperwork. The House just told them to.

The chamber passed the FDA Modernization Act 3.0 on July 20, directing the agency to rewrite regulations that still require animal studies before human trials, even though Congress lifted the statutory animal-test mandate four years ago. The bill is procedural in shape but consequential in scope: it would close the longest-running gap between what the law allows and what the FDA's rulebook says.

The bill's sponsor, Rep. Buddy Carter (R-Ga.), has framed it as a regulatory alignment, not a new preclinical-research regime. The companion Senate version passed in December under the bipartisan leadership of Sen. Cory Booker (D-N.J.) and Sen. Eric Schmitt (R-Mo.). The House version must clear the Senate again before reaching President Trump.

The point is the gap between statute and regulation. The 2022 FDA Modernization Act 2.0 removed the statutory requirement that drug developers run animal studies before testing a candidate in humans. It did not force the FDA to rewrite the agency regulations that still describe animal tests as the default pathway through preclinical safety and toxicity studies. Four years on, companies and regulators navigate an inconsistent rulebook: the statute says animal studies are not required, while the regulations describe them as the norm.

2821](https://www.govtrack.us/congress/bills/119/hr2821/text)) directs the FDA to bring those regulations into line. It also codifies the FDA's 2025 roadmap, which sets a three-to-five-year target for making animal studies the exception rather than the rule in preclinical safety and toxicity work. Codifying a posture is not the same as setting a deadline: the bill instructs the FDA to act, but the agency decides what "act" means.

The FDA is already moving in that direction. The agency has qualified an artificial-intelligence tool for evaluating liver-biopsy images, a step that lets a non-animal method substitute for animal-pathology reads in some studies. It has issued draft guidance encouraging developers of monoclonal antibodies (lab-made antibody drugs) to avoid primate studies when a validated non-animal method exists. The agency has also built a searchable online table of NAMs, or new approach methodologies: validated non-animal tests such as organ-on-chip devices, computer models, and cell-based assays that can stand in for whole-animal experiments, and has said it will consider NAM data not previously qualified for a specific use.

Trial conduct and the drug-approval pathway remain FDA-discretionary. The bill does not require any company to skip animal tests for any specific drug, and it does not shorten the agency's review clock. It forces the agency to convert its 2025 posture into regulation, with the public comment and rulemaking process that implies.

Wayne Pacelle, president of the Center for a Humane Economy, called the bill's imminent enactment "a path to scientifically superior, faster, cheaper drug development." The quote is on-record advocacy; it is not a neutral forecast. The non-animal methods the bill would encourage have matured fastest in narrow use cases, including liver-toxicity screening and certain antibody-safety studies, and slower in the kind of whole-body safety work regulators still need to weigh for novel drug classes. The bill does not resolve that scientific question. It instructs the FDA to ask it more often.

The Senate's December vote on a near-identical companion bill makes final passage plausible, not certain. Senate leadership would have to bring the House version to a floor vote or substitute its own text and send it back to the House. The next concrete step is a Senate vote; the next concrete product is the FDA's eventual rulemaking, with its own public comment clock.

If the bill becomes law, the meaningful change will not be a new preclinical-testing regime. It will be the date the FDA's rulebook finally catches up to 2022.